Aims From the various mechanical cardiac assist devices and indications available, the use of the percutaneous intraventricular Impella CP pump is usually restricted to acute ischaemic shock or prophylactic indications in high-risk interventions. In the present study, we investigated clinical usefulness of the Impella CP device in patients with non-ischaemic cardiogenic shock as compared with acute ischaemia.
Introduction
The Impella CP device (Abiomed, Danvers, MA) is indicated for short-term left ventricular mechanical support (≤4 days) in cardiogenic shock due to acute myocardial infarction (AMI) or planned cardiac surgery.
1 Current guidelines indicate a class IIb recommendation in patients with therapy refractory cardiogenic shock in ST-segment elevation myocardial infarction, due to little knowledge on survival benefits. 2 Even less is known regarding use of the Impella CP in patients with
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shock due to non-ischaemic origin. Limited time of operation and missing options for blood oxygenation might favour the use of alternative assist devices such as extracorporeal membrane oxygenation (ECMO) or tandem heart in these indications. However, the minimally invasive nature of Impella therapy and effective ventricular unloading, as compared with increased afterload in ECMO therapy, might in fact favour Impella CP use for bridge-to-recovery or destination therapy in such patients. The aim of this study was to investigate the role of Impella CP support in patients with non-ischaemic cardiogenic shock as compared with shock in AMI.
Methods
This single-centre retrospective case-control study investigated patients who received an Impella CP device due to acute non-ischaemic cardiogenic shock. Inclusion criteria were therapy refractory haemodynamic instability with severe left ventricular systolic dysfunction and serum lactate >2.0 mmol/L at implantation, with excluded AMI. Twentyfive patients were included and compared with 50 patients who received an Impella CP due to AMI with shock during the same period. Outcome measures were haemodialysis, ECMO, or left ventricular assist device implantation, heart transplantation, 30 day survival, and overall in-hospital mortality. For the univariate analysis, just one variable was fitting at a time in the logistic regression model in order to find which variable is individually predictive. Univariate predictors were analysed in a multivariate analysis. The odds ratio and 95% confidence interval were determined. Statistical analyses were performed using SPSS Statistics 24 (IBM). Continuous variables are expressed as mean ± standard deviation or median (quartiles). Categorical variables are presented as count and per cent.
Results
Mean age was 61 ± 13 (range 19-85) years, and 72% were male. Main underlying diseases for cardiogenic shock in the non-ischaemic group were dilated cardiomyopathy (n = 9; 36%), chronic ischaemic cardiomyopathy (n = 2; 7.7%), hypertrophic cardiomyopathy (n = 2; 7.7%), myocarditis (n = 2; 7.7%), catecholamine-induced cardiomyopathy due to pheochromocytoma (n = 1; 3.8%), non-compaction cardiomyopathy (n = 1; 3.8%), takotsubo cardiomyopathy (n = 1; 3.8%), and sarcoidosis (n = 1; 3.8%).
The need for resuscitation before Impella implantation was frequent in both groups (32 vs. Figure 1) . Several predictors for mortality were identified including serum lactate, ventilation time, haemoglobin, pH, SaO 2 , base Impella in non-ischaemic shock excess, glucose, bleeding anaemia, resuscitation, sepsis, and Impella time ( Table 2) . From the patients with non-ischaemic cardiogenic shock and without mechanical device support (ECMO and left ventricular assist device) or transplantation, only 24% (six from 25) survived. In the resuscitation group, only 21% (six from 29) survived, compared with 36% in the total cohort (27 from 75).
Conclusions
Thirty day mortality in our study generally was high, mainly driven by post-resuscitation mortality. However, overall survival rates were similar to those found in recent large shock trials. [3] [4] [5] Our current data suggest that benefit of Impella CP therapy might be similar in non-ischaemic compared with ischaemic shock. Moreover, a substantial percentage of patients without acute ischaemia recovered without further need for intensified haemodynamic mechanical support. Of note, a relatively large proportion of patients in the nonischaemic cohort initially suffered from chronic cardiomyopathies. Here, several alternatives for bridge-to-recovery or destination therapy are available. Just recently, feasibility of the larger Impella 5.0 in bridge-to-heart transplantation was demonstrated. 6 The current results position short-time use of the Impella CP as an alternative in the treatment of patients with cardiogenic shock due to underlying nonischaemic cardiomyopathy and/or complicating additional factors. However, additional studies are needed to test whether these findings can be confirmed in larger patient populations and which subgroups might benefit most from Impella therapy.
